<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Membranous nephropathy: Clinical manifestations and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Membranous nephropathy: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Membranous nephropathy: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurence H Beck, Jr, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David J Salant, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1485812613"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in adults without diabetes, accounting for up to one-third of biopsy diagnoses in some regions. The term MN reflects a pattern of injury found by histopathologic examination of the kidney biopsy: glomerular basement membrane (GBM) thickening and subepithelial immunoglobulin-containing deposits with little or no cellular proliferation or infiltration [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome", section on 'Etiology'</a>.)</p><p>Historically, MN was classified as either primary (or "idiopathic") or secondary, depending on the absence or presence, respectively, of diseases or exposures that were associated with and felt to be causative of the MN. Some examples of traditional secondary associations include hepatitis B antigenemia, autoimmune diseases (such as systemic lupus erythematosus [SLE]), thyroiditis, malignancies, and the use of certain drugs such as nonsteroidal antiinflammatory drugs (NSAIDs), alpha-lipoic acid, and certain traditional medicines. The discovery of the phospholipase A2 receptor (PLA2R) and, later, thrombospondin type-1 domain-containing 7A (THSD7A), two proteins expressed by the normal podocyte, established a prototype for "primary" disease in which a humoral autoimmune response against an antigen available at the basal surface of the podocyte leads to exclusively subepithelial deposits and kidney-restricted pathology. Since then, many additional autoantigens or putative antigens have been described in forms of MN that do not fully fit this prototype of primary MN, as the proteins are not expressed by the normal podocyte (eg, neural epidermal growth factor-like 1 [NELL1]) or more often occur in association with another condition. While the field is moving toward an antigen-based classification system, we will continue to utilize the more traditional terms of "primary" and "secondary" in this topic, with the caveat that many if not all forms of MN may have a trigger, known or unknown, that ultimately leads to the formation of autoantibodies and/or immune complexes that target the glomerulus and result in the lesion of MN.<strong> </strong></p><p>The clinical manifestations, pathology, and diagnosis of MN will be reviewed here. The epidemiology, pathogenesis, etiology, treatment, and prognosis of MN are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H1187721619"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3777197796"><span class="h2">Adults</span><span class="headingEndMark"> — </span>Most adult patients with MN (approximately 80 percent) present with the nephrotic syndrome; the remainder are diagnosed following an evaluation for asymptomatic proteinuria. Marked proteinuria in the absence of hypoalbuminemia is seldom seen, in contrast with secondary focal segmental glomerulosclerosis (FSGS). (See  <a class="medical medical_review" href="/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome"</a>.)</p><p>Because the underlying pathology is due to the gradual accumulation of subepithelial deposits and resultant podocyte damage, the features of the nephrotic syndrome, especially weight gain and lower extremity edema, develop at a slower pace than those observed in patients with minimal change disease or primary FSGS. Thus, the precise onset of disease is less likely to be noticed by the patient or clinician. </p><p>The amount of proteinuria is highly variable, ranging from subnephrotic (less than 3.5 g/day) to more than 20 g/day. Proteinuria is typically present for several months prior to the diagnosis of MN by kidney biopsy, which highlights the more gradual development of this disease process. Other common abnormalities on urinalysis and urine microscopy include oval fat bodies, lipid droplets, and fatty casts. Microscopic hematuria occurs in up to 50 percent, but red blood cell casts are rare [<a href="#rid2">2</a>]. Glucosuria in the presence of normal blood glucose levels is common in patients with nephrotic syndrome, probably a consequence of tubular dysfunction from the heavy albuminuria.</p><p>Severe hyperlipidemia is almost always present at diagnosis in patients with the nephrotic syndrome but usually not in patients with subnephrotic proteinuria. (See  <a class="medical medical_review" href="/d/html/3114.html" rel="external">"Lipid abnormalities in nephrotic syndrome"</a>.)</p><p>Approximately 70 percent of patients have normal blood pressure and glomerular filtration rate at presentation. Acute kidney injury is uncommon and may be due to hypovolemia due to aggressive diuresis, acute interstitial nephritis due to diuretics or other offending drugs, superimposed crescentic glomerulonephritis (which is associated with an active sediment), or, rarely, from acute renal vein thrombosis leading to renal infarction. (See  <a class="medical medical_review" href="/d/html/3047.html" rel="external">"Acute kidney injury (AKI) in minimal change disease and other forms of nephrotic syndrome"</a> and  <a class="medical medical_review" href="/d/html/7234.html" rel="external">"Clinical manifestations and diagnosis of acute interstitial nephritis", section on 'Drugs'</a> and  <a class="medical medical_review" href="/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a>.)</p><p>The usual course of patients with MN is either spontaneous or treatment-induced complete or partial remission or persistent nephrotic syndrome with or without slow progression to end-stage kidney disease  (<a class="graphic graphic_figure graphicRef61059" href="/d/graphic/61059.html" rel="external">figure 1</a>). The prognosis of MN is discussed separately. (See  <a class="medical medical_review" href="/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis", section on 'Prognosis'</a>.)</p><p>Patients with subnephrotic proteinuria have a benign long-term prognosis as long as they remain subnephrotic. However, these patients require long-term monitoring of protein excretion since many progress to nephrotic-range proteinuria, with its associated higher rate of progressive disease. The rationale for prolonged monitoring was provided by a review of 395 patients with MN, 108 (27 percent) of whom presented with subnephrotic proteinuria (less than 3.5 g/day) [<a href="#rid3">3</a>]. Among these patients, 66 (61 percent) progressed to nephrotic syndrome, 20 after the first year of follow-up, including nine after more than four years. (See  <a class="medical medical_review" href="/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis", section on 'Low risk of progression'</a>.)</p><p class="headingAnchor" id="H3335777282"><span class="h2">Children</span><span class="headingEndMark"> — </span>MN is an uncommon cause of nephrotic syndrome in children, and studies on the clinical features of pediatric MN are limited [<a href="#rid4">4-6</a>]. In general, children and adolescents with MN have a clinical presentation that is similar to that in adults with MN. The majority of patients present with nephrotic-range proteinuria and preserved kidney function; approximately two-thirds of patients have the nephrotic syndrome [<a href="#rid4">4,5</a>]. Microscopic hematuria can be seen in 30 to 60 percent [<a href="#rid4">4,5</a>]. In contrast with MN in adults, which has a male predominance, MN in children and adolescents appears to affect males and females equally.</p><p class="headingAnchor" id="H4252284183"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H3180069509"><span class="h2">Characteristic histologic features</span><span class="headingEndMark"> — </span>The characteristic histologic features of MN are described below. These findings are seen in both primary and secondary MN although there are certain histologic clues that are suggestive of secondary MN. (See <a class="local">'Features distinguishing primary and secondary MN'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Light microscopy </strong>– The characteristic histologic lesion on light microscopy is diffuse thickening of the glomerular basement membrane (GBM) throughout all glomeruli in the absence of significant hypercellularity  (<a class="graphic graphic_picture graphicRef74698 graphicRef55226 graphicRef69629 graphicRef62937 graphicRef69348" href="/d/graphic/74698.html" rel="external">picture 1A-E</a>) [<a href="#rid1">1</a>]. However, the glomeruli may appear entirely normal by light microscopy in early cases of MN, and "spikes" of GBM extending between the immune deposits may be seen with appropriate stains in more advanced cases. Chronic sclerosing glomerular and tubulointerstitial changes develop as the disease progresses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunofluorescence microscopy </strong>– Immunofluorescence microscopy reveals a diffuse granular pattern of immunoglobulin (Ig) G and C3 staining along the GBM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electron microscopy </strong>– The hallmark lesions on electron microscopy are subepithelial electron-dense deposits on the outer aspect of the GBM, effacement of the foot processes of the overlying podocyte, and expansion of the GBM by deposition of new extracellular matrix between the deposits (which are the "spikes" seen with special stains). Mesangial deposits of immunoglobulin are infrequently seen, and subendothelial deposits are virtually never seen in primary MN. While most patients with MN have globally distributed immune deposits, a rare subset of patients has segmental immune deposits (involving 25 to 75 percent of the GBM) [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Expansion of the GBM occurs over time as the immune deposits separate from the basal surface of the podocytes and become incorporated into the expanded GBM as new extracellular matrix is deposited by the injured podocytes. Thus, the disease may be staged according to the extent to which the subepithelial immune deposits are surrounded by the GBM. This staging, though, bears no relationship to the severity of the proteinuria or responsiveness to treatment. (See  <a class="medical medical_review" href="/d/html/3068.html" rel="external">"Mechanisms of immune injury of the glomerulus"</a>.) </p><p></p><p class="headingAnchor" id="H2361155227"><span class="h2">Features distinguishing primary and secondary MN</span><span class="headingEndMark"> — </span>The prototype for primary MN is phospholipase A2 receptor (PLA2R)-associated MN, in which an IgG4-predominant humoral response against a normal podocyte protein leads to exclusively subepithelial deposits and kidney-restricted pathology. Secondary MN occurs in response to infections, malignancies, systemic autoimmune diseases, and medications, such that elimination of the initiating process can lead to remission of the MN. The distinction between primary and secondary MN can be blurred when the target antigen and histopathology suggest primary disease, while another disease process, such as hepatitis B infection or concurrent malignancy, may raise the possibility of a secondary etiology. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology"</a>.)</p><p>In addition, the field of MN continues to rapidly evolve with the identification of new proteins that are enriched within the subepithelial immune deposits [<a href="#rid8">8</a>]. While some of these likely represent true glomerular antigens that are targeted in situ by circulating autoantibodies, others have been described as tissue biomarkers as no antibodies have been detected. It is not always possible to place each new MN-associated protein neatly into a primary or secondary category, and some have recommended classifying MN based upon the target antigen (or biomarker) when identified, commenting on the absence of presence of known or suspected secondary features or associations [<a href="#rid9">9,10</a>]. We will continue to use the terms primary and secondary in this topic review, referencing target antigens or biomarkers as appropriate.</p><p>Several histologic characteristics by immunofluorescence and electron microscopy have been identified that may help to distinguish between primary and secondary forms of MN (see  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Phospholipase A2 receptor'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunofluorescence characteristics</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The subepithelial immune deposits in primary MN predominantly stain positive for IgG and C3 by immunofluorescence. The presence of additional IgA, IgM, and C1q (a "full house" pattern) suggests the presence of a secondary etiology such as class V lupus nephritis. (See  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification", section on 'Lupus membranous nephropathy (class V)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of certain target antigens such as PLA2R, thrombospondin type-1 domain-containing 7A (THSD7A), or serine protease HTRA1 [<a href="#rid11">11</a>] within immune deposits in a fine, granular capillary-loop pattern by immunofluorescence or immunohistochemistry is strongly suggestive of primary MN  (<a class="graphic graphic_diagnosticimage graphicRef114640" href="/d/graphic/114640.html" rel="external">image 1</a>). (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Target antigens and autoantibodies'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The IgG deposits in PLA2R-associated and THSD7A-associated primary MN are predominantly IgG4, whereas predominance of other IgG isotypes has been described in certain causes of secondary MN [<a href="#rid12">12,13</a>] or in certain subtypes of antigen-defined MN (neural epidermal growth factor-like 1 [NELL1]-, semaphorin 3B [Sema3B]-, protocadherin 7 [PCDH7]-associated MN) [<a href="#rid9">9,14,15</a>]. As an example, in lupus-associated MN, IgG1 and IgG3 may predominate [<a href="#rid16">16,17</a>]; by contrast, a predominance of IgG1 and IgG2 has been reported in the putative malignancy-associated MN [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tubular basement membrane staining for IgG on immunofluorescence is rare in primary MN but is common in secondary forms such as systemic lupus erythematosus (SLE). In addition, some patients develop antitubular basement membrane antibodies with tubulointerstitial nephritis [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Granular GBM staining for exostosin-1 and exostosin-2, neural cell adhesion molecule 1 (NCAM1), or type III transforming growth factor beta receptor (TGFBR3) by immunostaining is suggestive of SLE or other underlying autoimmune disease [<a href="#rid20">20-22</a>]. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Other antigens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electron microscopy characteristics</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In primary MN, electron-dense deposits on electron microscopy are typically subepithelial and intramembranous. Mesangial deposits are uncommon but can be present [<a href="#rid23">23</a>]. The presence of mesangial and subendothelial deposits is suggestive of secondary forms of MN [<a href="#rid24">24-26</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of tubuloreticular structures in the glomerular endothelial cells (which are induced by interferon alpha) strongly suggests a diagnosis of lupus MN, which may present before the typical systemic and serologic manifestations of the disease. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Systemic lupus erythematosus and other autoimmune disorders'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In advanced MN, substantial remodeling and thickening of the GBM may be present. In exceptional cases the immune deposits may be scanty and electron lucent.</p><p></p><p class="headingAnchor" id="H1549791430"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1327015461"><span class="h2">When to suspect the diagnosis</span><span class="headingEndMark"> — </span>MN should be suspected in all adult patients who present with features of the nephrotic syndrome, such as unexplained proteinuria, hypoalbuminemia, and edema or weight gain. MN occurs uncommonly in children, but the diagnosis may be suspected in patients with steroid-resistant nephrotic syndrome. (See  <a class="medical medical_review" href="/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults", section on 'Nephrotic syndrome (heavy proteinuria and hypoalbuminemia)'</a> and  <a class="medical medical_review" href="/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology"</a>.)</p><p class="headingAnchor" id="H958840899"><span class="h2">Initial evaluation</span></p><p class="headingAnchor" id="H2529280415"><span class="h3">Evaluation for secondary causes</span><span class="headingEndMark"> — </span>In all patients who are suspected of having MN, we obtain a thorough history to determine if the patient has any potential secondary causes of MN, including the following  (<a class="graphic graphic_algorithm graphicRef115301" href="/d/graphic/115301.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Exposures to drugs and/or toxins associated with MN (eg, nonsteroidal antiinflammatory drugs [NSAIDs], alpha-lipoic acid, and certain mercury-containing traditional indigenous medicines [<a href="#rid27">27</a>] and skin-lightening creams) (see  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Drugs'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of infections (such as hepatitis B or C or syphilis) (see  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Infections'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of autoimmune diseases (such as systemic lupus erythematosus [SLE], Sjögren's disease, or autoimmune thyroiditis) (see  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Systemic lupus erythematosus and other autoimmune disorders'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of malignancy (see <a class="local">'Screening for malignancy'</a> below and  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Malignancy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of monoclonal gammopathy (see  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'MN with light chain–restricted deposits'</a> and  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Membranous-like nephropathy with masked IgG-kappa'</a>)</p><p></p><p>We then obtain the following laboratory and radiological studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Comprehensive chemistry panel including serum albumin</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis with examination of the urinary sediment</p><p class="bulletIndent1"><span class="glyph">●</span>24-hour urine collection for protein quantification or spot urine protein-to-creatinine ratio</p><p class="bulletIndent1"><span class="glyph">●</span>Antinuclear antibodies (ANA) and, if positive, anti-double-stranded DNA (anti-dsDNA), anti-Smith, anti-Ro/SSA, and anti-La/SSB antibodies</p><p class="bulletIndent1"><span class="glyph">●</span>Tests for hepatitis B and C viruses and human immunodeficiency virus (HIV)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum C3 and C4 complement levels</p><p class="bulletIndent1"><span class="glyph">●</span>In patients older than 50 years, serum free light chains (SFLCs) and serum protein electrophoresis (SPEP) with immunofixation</p><p class="bulletIndent1"><span class="glyph">●</span>Chest radiograph (or computed tomography of the chest in patients with a history of smoking or asbestos exposure)</p><p></p><p class="headingAnchor" id="H1039629400"><span class="h3">Anti-PLA2R antibody testing</span><span class="headingEndMark"> — </span>All patients with suspected MN should be tested for autoantibodies against the phospholipase A2 receptor (PLA2R), the major antigen in primary MN  (<a class="graphic graphic_algorithm graphicRef115301" href="/d/graphic/115301.html" rel="external">algorithm 1</a>). Commercially available tests include an indirect immunofluorescence assay (IFA) and an enzyme-linked immunosorbent assay (ELISA).</p><p>Patients with positive anti-PLA2R serology (ELISA and IFA), normal kidney function, and no evidence of secondary causes of MN or diabetes mellitus may be diagnosed with primary PLA2R-associated MN without the need for a kidney biopsy. However, a negative serological test for anti-PLA2R does not exclude a diagnosis of primary MN, as up to 20 percent of cases may be seronegative at presentation with nephrotic syndrome. (See <a class="local">'Establishing the diagnosis'</a> below.)</p><p>A discussion of the role of PLA2R in the pathogenesis of primary MN is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Phospholipase A2 receptor'</a>.)</p><p class="headingAnchor" id="H386381915"><span class="h4">Diagnostic utility</span><span class="headingEndMark"> — </span>The diagnostic utility of anti-PLA2R antibody testing is summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 70 to 80 percent of patients presumed to have primary MN have a positive test (ELISA and/or IFA). The IFA test is slightly more sensitive than the ELISA, but both are approximately equally specific for anti-PLA2R antibody at the time of kidney biopsy diagnosis of MN. By contrast, some patients with primary MN will have a negative anti-PLA2R antibody test. This may mean that the target antigen is not PLA2R; that the target antigen is PLA2R, but the patient is in immunologic remission; or that the target antigen is PLA2R, and the patient is in the early stages of the disease with deposition of all antibody in the glomerular deposits. In addition, a small percentage of patients presumed to have secondary MN will have a positive test for anti-PLA2R antibody; some of these patients may in fact have primary MN with superimposed but unrelated infection, autoimmune disease, cancer, or medication use [<a href="#rid28">28-30</a>]. Thus, a positive test, although highly suggestive of primary MN, does not exclude the coexistence of infection, malignancy, or another associated rheumatologic or inflammatory disease. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Phospholipase A2 receptor'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nephrotic patients without MN seldom (and perhaps never) have a positive test for the anti-PLA2R antibody. We are aware of rare cases with nephrotic syndrome with a positive ELISA and a pathological diagnosis other than MN [<a href="#rid31">31</a>]. However, in such cases the anti-PLA2R IFA was negative, indicating the nonspecificity of the ELISA. Thus, a truly positive anti-PLA2R serology by ELISA and IFA essentially rules out other causes of nephrotic syndrome (such as minimal change disease or focal segmental glomerulosclerosis [FSGS]) [<a href="#rid32">32,33</a>]. In our opinion, a positive ELISA and negative IFA should raise a question about the specificity of the ELISA result and is an indication to proceed to kidney biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with primary MN, testing for anti-PLA2R antibodies may provide additional information regarding treatment response. In one study involving 514 patients with primary MN and positive staining for PLA2R on kidney biopsy, patients with anti-PLA2R antibodies at the time of biopsy had a lower rate of complete remission (proteinuria of &lt;0.4 g/day) at 24 months compared with those without anti-PLA2R antibodies (36 versus 61 percent) [<a href="#rid34">34</a>]. In addition, some data suggest that a falling anti-PLA2R titer indicates that an immunological remission is underway, whereas a persistently high titer is associated with a less favorable clinical course [<a href="#rid32">32,34,35</a>]. (See  <a class="medical medical_review" href="/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis", section on 'Risk factors for disease progression'</a>.)</p><p></p><p class="bulletIndent1">Serial assessment of anti-PLA2R antibody titers may also be useful for monitoring the immunological activity of disease when treatment decisions are being considered. (see  <a class="medical medical_review" href="/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis", section on 'Clinical utility of anti-PLA2R antibody levels'</a>)</p><p></p><p class="headingAnchor" id="H1234426444"><span class="h4">Defining a positive result</span><span class="headingEndMark"> — </span>Assessment of seropositivity for anti-PLA2R can vary depending upon the specific assay used for its detection and quantitation and upon the cutoff value that defines a positive result. There are two US Food and Drug Administration-approved commercial assays available for anti-PLA2R: a cell-based IFA and an ELISA, both of which detect total IgG against PLA2R [<a href="#rid36">36</a>]. According to manufacturer instructions, a positive signal at 1:10 in the IFA defines seropositivity. In the ELISA, a clear positive assay is represented by a titer above 20 RU/mL, whereas a titer in the 14 to 20 RU/mL range is considered borderline. Many clinical laboratories, as well as most publications in the literature, use these definitions for seropositivity.</p><p>However, several experts have suggested that ELISA titers above a much lower cutoff of 2 to 3 RU/mL may be a better level to determine seropositivity [<a href="#rid37">37-40</a>] and can increase sensitivity of the test without sacrificing specificity. Studies comparing ELISA, IFA, and Western blotting for the detection of anti-PLA2R have shown that IFA is more sensitive for the detection of anti-PLA2R than ELISA when the cutoff for positivity is &gt;20 RU/mL [<a href="#rid38">38,41</a>]. As an example, in one study of 359 patients with primary MN, the seropositivity rate was 56 percent when an ELISA cutoff of 20 RU/mL was used, compared with 65 percent when IFA with a cutoff 1:10 was used [<a href="#rid41">41</a>]. However, the ELISA can perform as well as or better than the IFA when the cutoff is lowered to 2 RU/mL [<a href="#rid38">38</a>].</p><p>Several centers use both the ELISA and IFA to confirm seropositivity, especially when using the lower cutoff of 2 RU/mL [<a href="#rid37">37</a>]. In a cohort of 480 patients who had been tested by both methods for anti-PLA2R and had a biopsy of their native kidney, there were 110 cases in which the ELISA result was ≥2 and ≤20 RU/mL [<a href="#rid37">37</a>]. Thirty of these cases also had a positive IFA for anti-PLA2R, and all 30 (100 percent) showed MN on biopsy. However, among the 80 cases with a negative IFA, only 46 (57 percent) had evidence of MN on biopsy. Thus, we suggest that if a lower ELISA threshold is used to define seropositivity for anti-PLA2R, it should be confirmed with IFA or be used in a situation when a patient is initially known to be seropositive due to ELISA titers &gt;20 RU/mL and is being followed with serial titers for the achievement of immunological remission (ELISA titer &lt;2 RU/mL).</p><p class="headingAnchor" id="H2531437327"><span class="h3">Testing for other autoantibodies</span><span class="headingEndMark"> — </span>In addition to PLA2R, several other antigens or biomarkers have been identified among patients with MN. However, immunoassays for circulating antibodies are not widely available for most of these antigens, and, therefore, serological testing for these antibodies is not routinely performed in clinical practice. Anti-thrombospondin type-1 domain-containing 7A (THSD7A) and anti-neural epidermal growth factor-like 1 (NELL1) antibody testing (IFA or ELISA) may soon become more widely available. However, antibodies specific for these antigens are commercially available and can be used to stain kidney biopsy samples at specialized pathology laboratories to assess for the presence of these antigens within the immune deposits. (See <a class="local">'Negative serum anti-PLA2R antibody test'</a> below and  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Target antigens and autoantibodies'</a> and  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Other antigens'</a>.)</p><p class="headingAnchor" id="H4122393493"><span class="h2">Establishing the diagnosis</span><span class="headingEndMark"> — </span>Historically, a kidney biopsy was required to establish the diagnosis of MN; however, due to the identification of target antigens and the specificity of serologic assays for anti-PLA2R antibodies [<a href="#rid37">37,42,43</a>], we, and many clinicians, elect to begin with a serologic-based diagnostic approach  (<a class="graphic graphic_algorithm graphicRef115301" href="/d/graphic/115301.html" rel="external">algorithm 1</a>), particularly if there are relative contraindications to performing a biopsy. (See <a class="local">'Positive serum anti-PLA2R antibody test'</a> below and <a class="local">'Negative serum anti-PLA2R antibody test'</a> below.)</p><p>The validity of a serologic-based diagnostic approach was evaluated in a study of 838 patients who underwent serologic testing for anti-PLA2R antibodies as part of the evaluation for nephrotic syndrome or nephrotic-range proteinuria [<a href="#rid37">37</a>]. Of these patients, 132 tested positive for anti-PLA2R antibodies and had a native kidney biopsy performed; the primary diagnosis was MN in all biopsies. The following observations were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 60 patients who had positive anti-PLA2R antibodies, no secondary causes of MN, and preserved kidney function (estimated glomerular filtration rate [eGFR] &gt;60 mL/min/1.73 m<sup>2</sup>), only two (3 percent) had additional biopsy findings superimposed on the diagnosis of MN (FSGS in one patient and diabetic kidney disease in one patient), but these findings did not alter management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 37 patients who had positive anti-PLA2R antibodies, no secondary causes of MN, and impaired kidney function (eGFR &lt;60 mL/min/1.73 m<sup>2</sup>), kidney biopsy identified additional diagnostic findings in five patients (14 percent) that could have impacted management. These findings included acute interstitial nephritis, FSGS, acute tubular necrosis, crescentic glomerulonephritis, and diabetic nephropathy.</p><p></p><p class="bulletIndent1">A subsequent validation study in which the diagnosis of MN was confirmed by biopsy showed that in patients with preserved eGFR and no secondary causes of MN or diabetes, a positive anti-PLA2R antibody test (&gt;20 RU/mL by ELISA or a positive IFA) could confirm the diagnosis of MN without the need for a kidney biopsy [<a href="#rid44">44</a>]. (See <a class="local">'Diagnostic utility'</a> above.)</p><p></p><p class="bulletIndent1">These results suggest that a serologic-based diagnostic approach to MN is reasonable in patients with positive anti-PLA2R serology, no evidence of secondary causes of MN or diabetes mellitus, <strong>and</strong> normal kidney function. However, further validation of this approach in prospective studies is warranted to confirm these findings and to determine impact on long-term outcomes.</p><p></p><p class="headingAnchor" id="H2875569715"><span class="h3">Positive serum anti-PLA2R antibody test</span><span class="headingEndMark"> — </span>In patients with a positive serum anti-phospholipase A2 receptor (PLA2R) antibody test, the approach depends upon whether the patient has kidney function impairment and/or evidence of secondary disease (ie, positive testing for ANA and anti-dsDNA, hepatitis B or C, or HIV; low serum complement levels; abnormal SFLCs or SPEP; or radiographic findings consistent with sarcoidosis), diabetes, or atypical features (such as red blood cell or white blood cell casts on examination of the urinary sediment)  (<a class="graphic graphic_algorithm graphicRef115301" href="/d/graphic/115301.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>If the patient has normal kidney function <strong>and</strong> no evidence of secondary causes of MN, diabetes, or other atypical features, a diagnosis of primary PLA2R-associated MN can be established <strong>without</strong> the need to perform a kidney biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient has abnormal kidney function (ie, serum creatinine above the upper limit of the normal range adjusted for sex and age) <strong>or</strong> evidence of secondary causes of MN, diabetes, or other atypical features, we perform a kidney biopsy, unless contraindicated. Although such patients most likely have a diagnosis of primary PLA2R-associated MN based upon serologic testing, a biopsy is obtained to exclude secondary causes of MN and superimposed disease (eg, crescentic glomerulonephritis) and to evaluate the chronicity of kidney damage (such as the extent of glomerulosclerosis, tubular atrophy, and interstitial fibrosis). The evaluation of the kidney biopsy and subsequent approach is the same as that discussed below for patients with a negative serum anti-PLA2R antibody test. (See <a class="local">'Negative serum anti-PLA2R antibody test'</a> below.)</p><p></p><p class="headingAnchor" id="H1019342"><span class="h3">Negative serum anti-PLA2R antibody test</span><span class="headingEndMark"> — </span>In patients with a negative serum anti-phospholipase A2 receptor (PLA2R) antibody test (ELISA and IFA), we perform a kidney biopsy, unless contraindicated, to determine the cause of proteinuria and/or nephrotic syndrome  (<a class="graphic graphic_algorithm graphicRef115301" href="/d/graphic/115301.html" rel="external">algorithm 1</a>). If a kidney biopsy cannot be performed (due to patient preference, lack of availability, or contraindication to biopsy), we repeat serum anti-PLA2R antibody testing in three to four months since some patients with an initially negative serum antibody test may have delayed seroconversion [<a href="#rid45">45,46</a>]. If repeat serum anti-PLA2R testing is negative, a kidney biopsy should be performed, if possible. </p><p>Demonstration of the characteristic histologic features of MN on kidney biopsy confirms the diagnosis of MN (see <a class="local">'Characteristic histologic features'</a> above). In addition to routine light microscopy, immunofluorescence, and electron microscopy, staining for PLA2R should be performed:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive staining for PLA2R </strong>– Nearly all patients with positive staining for PLA2R have a diagnosis consistent with primary PLA2R-associated MN. The rare exception is in patients with positive PLA2R staining and restriction to a single light chain subtype (kappa or lambda) by immunofluorescence; such patients do not have a diagnosis of primary PLA2R-associated MN but rather a diagnosis of MN associated with monoclonal antibodies toward PLA2R. (See  <a class="medical medical_review" href="/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance"</a> and  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'MN with light chain–restricted deposits'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative staining for PLA2R </strong>– Patients with negative staining for PLA2R may have either primary or secondary MN, and further diagnostic testing may be required. This field is rapidly evolving as additional target antigens or biomarkers are being identified in cases of PLA2R-negative MN [<a href="#rid8">8</a>]. However, there are only a handful of immunoassays for circulating antibodies against these antigens, and most kidney pathologists are limited in their ability to stain the biopsy tissue for antigens other than PLA2R.</p><p></p><p class="bulletIndent1">Thus, when staining for PLA2R is negative, subsequent evaluation should be tailored according to which assays are most readily available  (<a class="graphic graphic_algorithm graphicRef139771" href="/d/graphic/139771.html" rel="external">algorithm 2</a>). Antibodies against NELL1, THSD7A, neural cell adhesion molecule 1 (NCAM1), semaphorin 3B (Sema3B), protocadherin 7 (PCDH7), exostosin 1 and 2 (EXT1/2), serine protease HTRA1, type III transforming growth factor beta receptor (TGFBR3), and netrin G1 (NTNG1) are commercially available; testing for some of these antigens is presently available in a few specialized pathology laboratories. It is important to note that in patients with de novo MN following kidney transplantation or MN associated with infections, medications, hematopoietic cell transplantation, or immunodeficiency, a known autoantigen may not be identified. Possible diagnostic approaches include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antigen-based staining </strong>– Some centers proceed to stain the kidney biopsy sample for other more frequently encountered target antigens (such as NELL1 and THSD7A) or biomarkers (such as EXT2). Positive staining for NELL1 or THSD7A may represent primary MN, but due to an increased association with malignancy, more frequent age- and risk-appropriate screening for cancer may be indicated if MN is determined to be associated with these antigens (see <a class="local">'Screening for malignancy'</a> below). The presence of EXT2 is often associated with systemic autoimmune disease such as SLE. Specialized kidney pathology centers may be able to stain for additional antigens or perform mass spectrometry of the kidney biopsy tissue to identify the enriched antigen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunoglobulin subclass staining </strong>– Other centers will determine the relative intensities of the IgG subclasses (IgG1, 2, 3, 4) within the immune deposits by immunostaining. A predominance or codominance of IgG4 suggests primary MN and can be seen in THSD7A-, HTRA1-, PCDH7-, and NTNG1-associated MN [<a href="#rid47">47</a>]. Predominance of IgG1 is more common with NELL1-, Sema3B-, EXT1/2-, and NCAM1-associated MN. The IgG subclass pattern in TGFBR3-associated MN is variable but can lack IgG4.</p><p></p><p class="bulletIndent2">Patients with negative staining of PLA2R <strong>and</strong> negative staining for IgG and its subclasses may have a diagnosis of "masked" MN. This diagnosis should be suspected when there is evidence of subepithelial deposits on electron microscopy resembling those in MN. In such patients, antigen retrieval methods (eg, pronase digestion) should be performed to determine if masked IgG deposits are present. Positive staining for serum amyloid P within the deposits may also support the diagnosis of this type of membranous-like nephropathy [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Staining guided by clinical and pathologic features</strong> – Another approach is to use the patient's clinical and pathologic features to guide additional staining of the kidney biopsy:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>History of autoimmune disease </strong>– For patients with a positive ANA or history of autoimmune disease, staining for EXT1/2, TGFBR3, or NCAM1 can detect approximately 40 percent of cases of MN that are secondary to autoimmune disease or lupus membranous nephropathy. In patients with chronic inflammatory demyelinating polyneuropathy, staining for contactin 1 (CNTN1) may identify cases of CNTN1-associated MN [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Systemic lupus erythematosus and other autoimmune disorders'</a> and  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Other antigens'</a> and  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Target antigens and autoantibodies'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Age </strong>– MN is rare in children. Staining for Sema3B may identify approximately 10 percent of pediatric cases of MN [<a href="#rid15">15</a>]. One study demonstrated that PLA2R and EXT1/2 were the most common antigens enriched in cases of pediatric MN, whereas one-third of patients did not have an identifiable antigen [<a href="#rid4">4</a>]. PLA2R-associated MN is more often seen in adolescents and is rare in individuals under the age of 10. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Other antigens'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Atypical biopsy features </strong>– Most patients with MN have diffuse and global distribution of immune deposits, which likely represents normal podocyte expression of the target protein. However, certain types of MN may exhibit a segmental pattern of immune deposits. This is most common with NELL1-associated MN [<a href="#rid7">7</a>] but can also rarely be seen with HTRA1-, EXT1/2-, NCAM1-, and TGFBR3-associated MN [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent3">Lack of staining for C3 on immunofluorescence can be observed with PCDH7-associated MN [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mass spectroscopy </strong>– Mass spectroscopic analysis of the tissue deposits is an emerging alternative to immunostaining and may soon be available as a clinical test at specialized centers to determine the subtype of MN in cases that are anti-PLA2R, anti-THSD7A, and anti-NELL1 negative.</p><p></p><p class="headingAnchor" id="H669604089"><span class="h2">Screening for malignancy</span><span class="headingEndMark"> — </span>Patients should have age- and risk-appropriate cancer screening, whether or not they are diagnosed with MN. (See  <a class="medical medical_review" href="/d/html/97819.html" rel="external">"Overview of preventive care in adults", section on 'Cancer screening'</a>.)</p><p>Some patients with MN will have an underlying malignancy, either overt or covert; however, such malignancies may not necessarily be causally related to the MN. In most patients, the cancer has already been diagnosed or is clinically apparent (overt) when the patient presents with proteinuria. Uncommonly, the diagnosis of MN precedes that of the malignancy [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Malignancy'</a>.)</p><p>Thus, patients without known cancer who are diagnosed with MN should undergo age- and risk-appropriate cancer screening, if not already performed. A diagnosis of MN should <strong>not</strong> prompt an extensive search for occult malignancy in the absence of some suggestive finding such an extensive smoking history, guaiac-positive stools, or unexplained anemia or weight loss. Although microscopic hematuria is common in MN, cystoscopy is indicated among patients with risk factors for bladder cancer. (See  <a class="medical medical_review" href="/d/html/7208.html" rel="external">"Etiology and evaluation of hematuria in adults", section on 'Risk factors for malignancy'</a> and  <a class="medical medical_review" href="/d/html/97819.html" rel="external">"Overview of preventive care in adults", section on 'Cancer screening'</a>.)</p><p>A positive test for anti-PLA2R also makes it much less likely that the patient has cancer-associated MN [<a href="#rid29">29</a>]. Patients with a positive anti-PLA2R antibody test and/or those whose kidney histology is consistent with primary MN therefore only require cancer screening at the same frequency as the general population.</p><p>However, if the anti-PLA2R antibody test is negative or the kidney histology is consistent with secondary MN and if there is no other clear cause of secondary MN, then such patients require, in our opinion, more frequent age- and risk-appropriate screening for malignancy. In one study of patients with biopsy-proven MN, a negative test for serum anti-PLA2R conferred a nearly 10-fold higher risk of malignancy [<a href="#rid29">29</a>]. Increased frequency of cancer screening should continue for a period of 5 to 10 years after the diagnosis of MN since cancers associated with MN are typically diagnosed within this time frame. (See  <a class="medical medical_review" href="/d/html/97819.html" rel="external">"Overview of preventive care in adults", section on 'Cancer screening'</a>.)</p><p class="headingAnchor" id="H3594421474"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H3820830639"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in adults without diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– Most patients with MN present with the nephrotic syndrome, but some have only asymptomatic sub-nephrotic-range proteinuria. The serum creatinine is generally normal or near normal on initial presentation, and the majority of patients are normotensive. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology </strong>– MN is characterized pathologically by diffuse thickening of the glomerular basement membrane (GBM) on light microscopy; "spikes" on silver stain; diffuse, granular IgG and complement deposition on immunofluorescence; and subepithelial dense deposits on electron microscopy  (<a class="graphic graphic_picture graphicRef74698 graphicRef55226 graphicRef69629 graphicRef62937 graphicRef69348" href="/d/graphic/74698.html" rel="external">picture 1A-E</a>). (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– MN should be suspected in all adult patients who present with features of the nephrotic syndrome.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial evaluation </strong>– In all patients suspected of having MN, we obtain a thorough history to assess for any potential secondary causes of MN and obtain selected laboratory and radiological studies as detailed above. All patients should be tested for autoantibodies against the phospholipase A2 receptor (PLA2R), the major antigen in primary MN. (See <a class="local">'Evaluation for secondary causes'</a> above and <a class="local">'Anti-PLA2R antibody testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Establishing the diagnosis </strong>– Historically, a kidney biopsy was required to establish the diagnosis of MN; however, due to the identification of target antigens and the specificity of serologic assays for anti-PLA2R antibodies, many clinicians elect to begin with a serologic-based diagnostic approach, particularly if there are relative contraindications to performing a biopsy  (<a class="graphic graphic_algorithm graphicRef115301" href="/d/graphic/115301.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef139771" href="/d/graphic/139771.html" rel="external">algorithm 2</a>). A serologic-based approach may obviate the need for a kidney biopsy in patients with positive anti-PLA2R serology, normal kidney function, no history of diabetes, and no evidence of secondary causes of MN. (See <a class="local">'Establishing the diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Screening for malignancy </strong>– Patients with MN should have age- and risk-appropriate cancer screening if it has not already been performed. The frequency of cancer screening after a diagnosis of MN depends, in part, upon whether or not the disease is primary or secondary and, if secondary, whether or not there is another clear cause of secondary MN. (See <a class="local">'Screening for malignancy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology: Membranous Nephropathy. Am J Kidney Dis 2015; 66:e15.</a></li><li><a class="nounderline abstract_t">Wasserstein AG. Membranous glomerulonephritis. J Am Soc Nephrol 1997; 8:664.</a></li><li><a class="nounderline abstract_t">Hladunewich MA, Troyanov S, Calafati J, et al. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 2009; 4:1417.</a></li><li><a class="nounderline abstract_t">Kouri AM, Caza TN, Beck LH Jr, et al. Clinical and Histopathologic Characteristics of Pediatric Patients With Primary Membranous Nephropathy. Kidney Int Rep 2023; 8:2368.</a></li><li><a class="nounderline abstract_t">Miller P, Lei L, Charu V, et al. Clinicopathologic features of non-lupus membranous nephropathy in a pediatric population. Pediatr Nephrol 2022; 37:3127.</a></li><li><a class="nounderline abstract_t">Chen A, Frank R, Vento S, et al. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. BMC Nephrol 2007; 8:11.</a></li><li><a class="nounderline abstract_t">Kudose S, Santoriello D, Debiec H, et al. The clinicopathologic spectrum of segmental membranous glomerulopathy. Kidney Int 2021; 99:247.</a></li><li><a class="nounderline abstract_t">Caza TN, Al-Rabadi LF, Beck LH Jr. How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy. Front Immunol 2021; 12:800242.</a></li><li><a class="nounderline abstract_t">Sethi S. New 'Antigens' in Membranous Nephropathy. J Am Soc Nephrol 2021; 32:268.</a></li><li><a class="nounderline abstract_t">Bobart SA, Tehranian S, Sethi S, et al. A Target Antigen-Based Approach to the Classification of Membranous Nephropathy. Mayo Clin Proc 2021; 96:577.</a></li><li><a class="nounderline abstract_t">Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy. J Am Soc Nephrol 2021; 32:1666.</a></li><li><a class="nounderline abstract_t">Hemminger J, Nadasdy G, Satoskar A, et al. IgG Subclass Staining in Routine Renal Biopsy Material. Am J Surg Pathol 2016; 40:617.</a></li><li><a class="nounderline abstract_t">Yeo MK, Kim YH, Choi DE, et al. The Usefulness of Phospholipase A2 Receptor and IgG4 Detection in Differentiation Primary Membranous Nephropathy From Secondary Membranous Nephropathy in Renal Biopsy. Appl Immunohistochem Mol Morphol 2018; 26:591.</a></li><li><a class="nounderline abstract_t">Sethi S, Madden B, Debiec H, et al. Protocadherin 7-Associated Membranous Nephropathy. J Am Soc Nephrol 2021; 32:1249.</a></li><li><a class="nounderline abstract_t">Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int 2020; 98:1253.</a></li><li><a class="nounderline abstract_t">Haas M. IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. Am J Kidney Dis 1994; 23:358.</a></li><li><a class="nounderline abstract_t">Kuroki A, Shibata T, Honda H, et al. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med 2002; 41:936.</a></li><li><a class="nounderline abstract_t">Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004; 19:574.</a></li><li><a class="nounderline abstract_t">Katz A, Fish AJ, Santamaria P, et al. Role of antibodies to tubulointerstitial nephritis antigen in human anti-tubular basement membrane nephritis associated with membranous nephropathy. Am J Med 1992; 93:691.</a></li><li><a class="nounderline abstract_t">Sethi S, Madden BJ, Debiec H, et al. Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. J Am Soc Nephrol 2019; 30:1123.</a></li><li><a class="nounderline abstract_t">Caza TN, Hassen SI, Kenan DJ, et al. Transforming Growth Factor Beta Receptor 3 (TGFBR3)-Associated Membranous Nephropathy. Kidney360 2021; 2:1275.</a></li><li><a class="nounderline abstract_t">Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. Kidney Int 2021; 100:171.</a></li><li><a class="nounderline abstract_t">Larsen CP, Messias NC, Silva FG, et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 2013; 26:709.</a></li><li><a class="nounderline abstract_t">Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983; 24:377.</a></li><li><a class="nounderline abstract_t">Takekoshi Y, Tochimaru H, Nagata Y, Itami N. Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy. Kidney Int Suppl 1991; 35:S34.</a></li><li><a class="nounderline abstract_t">Davenport A, Maciver AG, Hall CL, MacKenzie JC. Do mesangial immune complex deposits affect the renal prognosis in membranous glomerulonephritis? Clin Nephrol 1994; 41:271.</a></li><li><a class="nounderline abstract_t">Kurien AA, Prema Ks J, Walker PD, Caza TN. Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy. Kidney Int 2022; 102:1424.</a></li><li><a class="nounderline abstract_t">Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22:1137.</a></li><li><a class="nounderline abstract_t">Timmermans SA, Ayalon R, van Paassen P, et al. Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. Am J Kidney Dis 2013; 62:1223.</a></li><li><a class="nounderline abstract_t">Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011; 26:2526.</a></li><li><a class="nounderline abstract_t">Hoxha E, Reinhard L, Castedello T, Becker JU. False positivity for PLA2R1 antibody measured by ELISA in a nephrotic patient with no membranous nephropathy. Kidney Int 2023; 103:411.</a></li><li><a class="nounderline abstract_t">Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1735.</a></li><li><a class="nounderline abstract_t">Hofstra JM, Wetzels JF. Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues. J Am Soc Nephrol 2014; 25:1137.</a></li><li><a class="nounderline abstract_t">Qin HZ, Zhang MC, Le WB, et al. Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy. J Am Soc Nephrol 2016; 27:3195.</a></li><li><a class="nounderline abstract_t">Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 2013; 83:940.</a></li><li><a class="nounderline abstract_t">Dähnrich C, Komorowski L, Probst C, et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 2013; 421:213.</a></li><li><a class="nounderline abstract_t">Bobart SA, De Vriese AS, Pawar AS, et al. Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int 2019; 95:429.</a></li><li><a class="nounderline abstract_t">Timmermans SA, Damoiseaux JG, Heerings-Rewinkel PT, et al. Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study. Am J Clin Pathol 2014; 142:29.</a></li><li><a class="nounderline abstract_t">Liu Y, Li X, Ma C, et al. Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients. Clin Chim Acta 2018; 476:9.</a></li><li><a class="nounderline abstract_t">Tampoia M, Migliucci F, Villani C, et al. Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy. J Nephrol 2018; 31:899.</a></li><li><a class="nounderline abstract_t">Qu Z, Zhang MF, Cui Z, et al. Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy. Am J Nephrol 2018; 48:438.</a></li><li><a class="nounderline abstract_t">De Vriese AS, Glassock RJ, Nath KA, et al. A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrol 2017; 28:421.</a></li><li><a class="nounderline abstract_t">Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol 2017; 12:983.</a></li><li><a class="nounderline abstract_t">Bobart SA, Han H, Tehranian S, et al. Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy: A Validation Study. Clin J Am Soc Nephrol 2021; 16:1833.</a></li><li><a class="nounderline abstract_t">van de Logt AE, Hofstra JM, Wetzels JF. Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. Kidney Int 2015; 87:1263.</a></li><li><a class="nounderline abstract_t">Ramachandran R, Kumar V, Nada R, Jha V. Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy. Kidney Int 2015; 88:1198.</a></li><li><a class="nounderline abstract_t">Hoxha E, Reinhard L, Stahl RAK. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol 2022; 18:466.</a></li><li><a class="nounderline abstract_t">Larsen CP, Sharma SG, Caza TN, et al. Serum amyloid P deposition is a sensitive and specific feature of membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 2020; 97:602.</a></li><li><a class="nounderline abstract_t">Le Quintrec M, Teisseyre M, Bec N, et al. Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. Kidney Int 2021; 100:1240.</a></li><li><a class="nounderline abstract_t">Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. Am J Kidney Dis 1993; 22:5.</a></li></ol></div><div id="topicVersionRevision">Topic 117886 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26300203" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : AJKD Atlas of Renal Pathology: Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10495797" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Membranous glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661220" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The natural history of the non-nephrotic membranous nephropathy patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38025223" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical and Histopathologic Characteristics of Pediatric Patients With Primary Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35333973" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinicopathologic features of non-lupus membranous nephropathy in a pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17683621" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32599086" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The clinicopathologic spectrum of segmental membranous glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34899763" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33380523" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : New 'Antigens' in Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33673911" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A Target Antigen-Based Approach to the Classification of Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33952630" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26848798" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : IgG Subclass Staining in Routine Renal Biopsy Material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28362702" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Usefulness of Phospholipase A2 Receptor and IgG4 Detection in Differentiation Primary Membranous Nephropathy From Secondary Membranous Nephropathy in Renal Biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33833079" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Protocadherin 7-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32534052" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8128936" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12487163" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767011" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1466368" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Role of antibodies to tubulointerstitial nephritis antigen in human anti-tubular basement membrane nephritis associated with membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31061139" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35369660" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Transforming Growth Factor Beta Receptor 3 (TGFBR3)-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33045259" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23196797" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6358633" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pathologic differentiation between lupus and nonlupus membranous glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1837572" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8050206" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Do mesangial immune complex deposits affect the renal prognosis in membranous glomerulonephritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36096266" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21566055" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Anti-phospholipase A2 receptor antibody in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24021909" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21633097" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36208829" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : False positivity for PLA2R1 antibody measured by ELISA in a nephrotic patient with no membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22956816" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24610931" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26989120" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23364522" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23541686" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30665573" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24926082" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29126817" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Serum anti-PLA2R antibody as a diagnostic biomarker of idiopathic membranous nephropathy: The optimal cut-off value for Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30187382" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30472708" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27777266" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A Proposal for a Serology-Based Approach to Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28550082" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Primary Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34782349" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Noninvasive Diagnosis of PLA2R-Associated Membranous Nephropathy: A Validation Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26024039" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26579688" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35484394" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Membranous nephropathy: new pathogenic mechanisms and their clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32001064" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Serum amyloid P deposition is a sensitive and specific feature of membranous-like glomerulopathy with masked IgG kappa deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34600965" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8322793" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Membranous glomerulonephritis and malignancy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
